Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized trial of MK-0616 in adults with hypercholesterolemia
jRCT2031210701Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of enlicitide in hypercholesterolemia and atherosclerotic disease (5 arms), sponsored by Merck & Co. Primary endpoints: Percent change from baseline in LDL-C at Week 8, Percentage of participants with one or more adverse events and 1 more. Started Mar 2022; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on jRCT2031210701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210701.